NKGen Biotech

NKGen Biotech LT Debt/Equity

The Long-Term Debt to Equity Ratio of NKGen Biotech (NKGN) as of Nov 22, 2026 is -0.17.

LT Debt/Equity

-0.17

Last updated:

Long-Term Debt to Equity Ratio of NKGen Biotech is 2023 -0.17 . Long-Term Debt to Equity Ratio of NKGen Biotech was 2022 - . It decreases by % lower compared to the previous year.

The NKGen Biotech LT Debt/Equity history

The NKGen Biotech LT Debt/Equity history
YEARLT Debt/EquityYoY
-0.17—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

NKGen Biotech Stock analysis

What does NKGen Biotech do? NKGen Biotech Inc develops autologous and allogeneic NK cell therapies for neurodegenerative and oncological diseases using its SuperNK platform. The company commercializes SNK01 for neurodegenerative diseases and SNK02 for cancer through clinical trials. Autologous NK cell immunotherapy involves harvesting pure NK cells from patients, activating them, and reinfusing them to enhance immune function and eliminate abnormal cells. The company focuses on treating cancer and neurodegenerative conditions with its SNK platform therapies. NKGen Biotech Inc's revenue model is based on conducting clinical trials for SNK01 and SNK02, with potential future commercialization of these therapies. The company is clinical-stage, meaning it generates income through research and development funding rather than product sales. Its primary focus is on developing therapies for cancer and neurodegenerative diseases using autologous and allogeneic NK cell approaches. The company's SNK platform enables the development of therapies that use pure NK cells harvested from patients' blood, activated, and reinfused to improve immune system function. This approach targets cancer, autoimmune, and neurodegenerative diseases. NKGen Biotech Inc's business model centers on advancing these therapies through clinical trials to reach commercialization stage. NKGen Biotech is one of the most popular companies on Eulerpool.

Frequently Asked Questions about NKGen Biotech stock

Long-Term Debt to Equity Ratio of NKGen Biotech is -0.17 in 2023.

On Eulerpool you can find the complete historical development of Long-Term Debt to Equity Ratio NKGen Biotech since 2006 – with annual values, charts, and detailed analysis.

The LT Debt/Equity ratio measures long-term financial leverage. It shows how much permanent debt capital is used relative to equity financing.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Long-Term Debt to Equity Ratio's NKGen Biotech with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — NKGen Biotech

All Key Metrics — NKGen Biotech